tirzepatide data Tirzepatide: A Systematic Update Tirzepatide Delivers Long-Term Weight Loss

According to FDA labeling for Wegovy (semaglutide), patients should be evaluated after 12 weeks at the maintenance dose (2.4 mg weekly), with discontinuation considered if less than 5% body weight reduction has been achieved

Two meta-analyses indicated treatment with melatonin improved liver enzyme levels, particularly when used for four weeks or longer

Individuals with high oxidative stress from chronic alcohol consumption, smoking, or environmental toxin exposure, all of which deplete hepatic glutathione stores

Therefore, GLP-1RA treatment alone may not address all relevant mechanisms and is more likely to serve as an adjunct therapy